New England Journal of Medicine· 2015Q1

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson et al.

2,083citations
Q1SCImago
2015year

Short summary

Lenvatinib significantly improved progression-free survival (18.3 months vs. 3.6 months) and response rates (64.8% vs. 1.5%) in patients with radioiodine-refractory thyroid cancer compared to placebo.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine